Kancera AB
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (US 11,660,303) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom (US 11,691,988) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (US 10,550,113) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,947,693 | 5,7-Disubstituted Thiazolo[4,5-d]pyrimidines as Chemokine Inhibitors In force · High confidence | In force | High confidence | |
| US 7,960,395 | 5,7-Disubstituted Thiazolo[4,5-d]pyrimidines for the Selective Inhibition of Chemokine Receptors In force · High confidence | In force | High confidence | |
| US 10,550,113 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,660,303 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,542,281 | A Process for the Steroselective Preparation of Chiral 2-[(HETERO)ARYLALKYLSULFANYL]PYRIMIDINES and Products Obtainable Therefrom In force · High confidence | In force | High confidence | |
| US 11,691,988 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom In force · Medium confidence | In force | Medium confidence | |
| US 12,264,165 | Process for the Stereoselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom In force · High confidence | In force | High confidence | |
| US 11,339,183 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 In force · From the USPTO record | In force | From the USPTO record | |
| US 12,060,380 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 8 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded